PAREXEL International

488 articles with PAREXEL International

• Parexel Appoints Gavin Nichols to Lead Informatics and Information Technology

  8/5/2019

  Parexel, a leading provider of solutions to accelerate the development and delivery of innovative new therapies to market to improve world health, from Clinical through to Commercialization, today announced Gavin Nichols has joined the company as Executive Vice President, Informatics and Information Technology.

• Parexel’s Peyton Howell Named to 2019 PharmaVOICE 100

  8/1/2019

  EVP and Chief Commercial & Strategy Officer recognized as one of the 100 most inspiring people in life sciences for healthcare industry leadership and patient focus

• Parexel Extends Asia/Pacific Capability with the Launch of Health Advances Asia Limited

  7/23/2019

  Strategic Healthcare Consulting subsidiary will support development of global expansion strategies for Asia/Pacific and multinational companies from new Hong Kong presence; biopharma and medtech veteran Gary Cheng to lead local team

• Parexel Launches Enhanced Integrated Functional Service Provider Model to Drive Delivery of Innovative Clinical Research Partnerships

  6/23/2019

  Parexel FSP provides biopharmaceutical customers the full spectrum of outsourcing solutions from full service to functional to a hybrid approach across a range of specialized disciplines including Clinical, Data Management, Safety, Regulatory and Medical Affairs

• Parexel Strengthens Risk-Based Monitoring Offering with New Advanced Statistical Capabilities

  6/18/2019

  Strategic collaboration leverages CluePoints’ Central Statistical Monitoring (CSM) technology to enhance data quality and reduce operational costs

• Parexel Teams with CLARINESS to Enhance Patient Access and Engagement in China

  6/12/2019

  Collaboration expands Parexel’s capabilities in the region for patient access through China’s native social media channels; enhances ongoing engagement through CLARINESS’s digital patient recruitment portal

• 

  Recent Facility and Job Expansions in the Biopharma Industry

  6/7/2019

  There has been a spate of recent news regarding the expansion of facilities and the expected job growth for the biopharma and life sciences industry. Here’s a look at some of those stories.

• Parexel Unveils Oncology Center of Excellence to Support Acceleration of Patient-Focused Oncology Drug Development

  5/29/2019

  Parexel International, a leader in supporting the biopharma industry in oncology drug development, unveiled its Oncology Center of Excellence.

• PAREXEL Ranked #1 Among Global CROs for Leadership in Phase II/III Clinical Research in Prominent Annual ISR CRO Quality Benchmark Survey

  4/2/2019

  Company recognized for service provider leadership among global customers

• 

  BioSpace Movers and Shakers: March 15

  3/15/2019

  Biotech and pharma companies make changes to their executive leadership teams, with moves at Sandoz, PAREXEL, FSD, Karuna, Precision Bio, and more.

• PAREXEL Expands Oncology Expertise Through FDA and Medical Oncologist Appointments

  2/27/2019

  Additions support increased demand and complexity in oncology drug development and commercialization

• 

  BioSpace Movers and Shakers: Feb. 15

  2/15/2019

  Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more.

• PAREXEL Appoints Former FDA Senior Executives to Global Regulatory Consulting Services

  2/12/2019

  The new additions join more than 60 former global regulators in the group and will be focused on helping companies understand and work within the current FDA and global regulatory climates to optimize drug development and mitigate risk of unnecessary delays.

• PAREXEL Receives Consecutive Recognitions from Forbes and FlexJobs for its Workplace Culture

  1/28/2019

  Company has once again been recognized for its diverse and flexible workplace by Forbes and FlexJobs.

• PAREXEL Introduces New Dedicated Division to Help Emerging Biotech Companies Reach their Goals Quickly and Cost-Effectively

  1/6/2019

  PAREXEL International Corporation today introduced a new, dedicated division to support emerging biotech companies in reaching their drug development and commercialization goals quickly and cost-effectively.

• PAREXEL Recognized with Awards for Innovation and Expertise in Real-World Evidence

  12/17/2018

  Recognitions include first-ever Scrip Award for Best Use of Real-World Evidence and “Best in Show” Fierce Innovation Award for partnership with Datavant, as FDA issues framework highlighting potential of RWE to industry

• PAREXEL Announces Change to Board of Directors

  12/13/2018

  Josef von Rickenbach will step down as Chairman of the Board of Directors effective December 31, 2018.

• PAREXEL Collaborates with Eli Lilly and Company to Develop China’s Clinical Research Workforce

  12/5/2018

  The program will bring high-value training opportunities to China’s clinical trial sites and investigators, enhancing the execution of local clinical trials and driving innovation in China’s biopharmaceutical industry.

• 

  Roivant Sciences Raises $200 Million, Bringing Its Valuation to $7 Billion

  11/13/2018

  Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.

• PAREXEL Announces Appointment of New Members to Its Board of Directors

  11/12/2018

  Today announced the appointment of new members to the Board of Directors following Pamplona Capital Management’s acquisition in September 2017.